Frontiers in Pharmacology,
Journal Year:
2022,
Volume and Issue:
13
Published: Aug. 19, 2022
Introduction:
Alzheimer's
disease
(AD)
is
a
severe
dementia
with
clinical
and
pathological
heterogeneity.
Our
study
was
aim
to
explore
the
roles
of
endoplasmic
reticulum
(ER)
stress-related
genes
in
AD
patients
based
on
interpretable
machine
learning.
Methods:
Microarray
datasets
were
obtained
from
Gene
Expression
Omnibus
(GEO)
database.
We
performed
nine
learning
algorithms
including
AdaBoost,
Logistic
Regression,
Light
Gradient
Boosting
(LightGBM),
Decision
Tree
(DT),
eXtreme
(XGBoost),
Random
Forest,
K-nearest
neighbors
(KNN),
Naïve
Bayes,
support
vector
machines
(SVM)
screen
ER
feature
estimate
their
efficiency
these
for
early
diagnosis
AD.
ROC
curves
evaluate
model
performance.
Shapley
additive
explanation
(SHAP)
applied
interpreting
results
models.
classified
using
consensus
clustering
algorithm.
Immune
infiltration
functional
enrichment
analysis
via
CIBERSORT
GSVA,
respectively.
CMap
utilized
identify
subtype-specific
small-molecule
compounds.
Results:
Higher
levels
immune
found
individuals
markedly
linked
deregulated
genes.
The
SVM
exhibited
highest
AUC
(0.879),
accuracy
(0.808),
recall
(0.773),
precision
(0.809).
Six
characteristic
(RNF5,
UBAC2,
DNAJC10,
RNF103,
DDX3X,
NGLY1)
determined,
which
enable
precisely
predict
progression.
SHAP
plots
illustrated
how
gene
influence
output
prediction
model.
Patients
could
obtain
benefits
gene-based
nomogram.
Two
subtypes
defined
AD,
subtype2
elevated
score,
as
well
higher
expression
checkpoint.
finally
identified
several
Conclusion:
provides
new
insights
into
role
stress
heterogeneity
development
novel
targets
individualized
treatment
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(22), P. 13954 - 13954
Published: Nov. 12, 2022
Alzheimer’s
disease
(AD)
is
the
most
frequent
case
of
neurodegenerative
and
becoming
a
major
public
health
problem
all
over
world.
Many
therapeutic
strategies
have
been
explored
for
several
decades;
however,
there
still
no
curative
treatment,
priority
remains
prevention.
In
this
review,
we
present
an
update
on
clinical
physiological
phase
AD
spectrum,
modifiable
non-modifiable
risk
factors
treatment
with
focus
prevention
strategies,
then
research
models
used
in
AD,
followed
by
discussion
limitations.
The
methods
can
significantly
slow
evolution
are
currently
best
strategy
possible
before
advanced
stages
disease.
Indeed,
current
drug
treatments
only
symptomatic
effects,
disease-modifying
not
yet
available.
Drug
delivery
to
central
nervous
system
complex
process
represents
challenge
developing
preventive
strategies.
Studies
underway
test
new
techniques
facilitate
bioavailability
molecules
brain.
After
deep
study
literature,
find
use
soft
nanoparticles,
particular
nanoliposomes
exosomes,
as
innovative
approach
reducing
solving
problems
brain
bioavailability.
show
promising
role
exosomes
smart
systems
able
penetrate
blood–brain
barrier
target
tissues.
Finally,
different
administration
neurological
disorders
discussed.
One
intranasal
which
should
be
preclinical
studies
diseases.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(18)
Published: Jan. 15, 2024
Abstract
Mitochondria,
widely
known
as
the
energy
factories
of
eukaryotic
cells,
have
a
myriad
vital
functions
across
diverse
cellular
processes.
Dysfunctions
within
mitochondria
serve
catalysts
for
various
diseases,
prompting
widespread
demise.
Mounting
research
on
remedying
damaged
indicates
that
constitute
valuable
target
therapeutic
intervention
against
diseases.
But
less
clinical
practice
and
lower
recovery
rate
imply
limitation
traditional
drugs,
which
need
further
breakthrough.
Nanotechnology
has
approached
favorable
regiospecific
biodistribution
high
efficacy
by
capitalizing
excellent
nanomaterials
targeting
drug
delivery.
Mitochondria‐remedying
nanodrugs
achieved
ideal
effects.
This
review
elucidates
significance
in
cells
organs,
while
also
compiling
mortality
data
related
Correspondingly,
nanodrug‐mediate
strategies
applicable
mitochondria‐remedying
disease
are
detailed,
with
full
understanding
roles
dysfunction
advantages
nanodrugs.
In
addition,
future
challenges
directions
discussed.
conclusion,
this
provides
comprehensive
insights
into
design
development
nanodrugs,
aiming
to
help
scientists
who
desire
extend
their
fields
engage
interdisciplinary
subject.
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 10, 2025
Alzheimer's
disease
(AD)
is
a
distinctive
form
of
dementia
characterized
by
age-related
cognitive
decline
and
memory
impairment.
A
key
hallmark
AD
the
irreversible
overaccumulation
beta-amyloid
(Aβ)
in
brain,
associated
with
neuroinflammation
neuronal
death.
Although
Aβ
clearance
immunoregulation
have
been
major
therapeutic
strategies
for
AD,
highly
selective
transport
across
blood–brain
barrier
(BBB)
negatively
affects
delivery
efficacy
drugs
without
ability
to
cross
BBB.
In
this
review,
we
discuss
potential
lipid-based
nanoparticles
(LBNs)
as
promising
vehicles
drug
treatment.
LBNs,
composed
phospholipid
mono-
or
bilayer,
attracted
attention
due
their
exceptional
cellular
penetration
capabilities
loading
capabilities,
which
also
facilitate
cargo
transcytosis
Recent
advances
development
engineering
LBNs
overcome
existing
limitations
current
clinical
approaches
treatment
addressing
off-target
effects
low
efficacy.
Here,
review
pathways
BBB,
well
various
types
therapy,
including
exosomes,
liposomes,
solid
lipid
(SLNs),
nanostructured
carriers
(NLCs),
elucidate
properties,
preparation
methodologies,
efficacy,
thereby
offering
innovative
avenues
novel
translation
therapy.
Small,
Journal Year:
2022,
Volume and Issue:
18(14)
Published: Feb. 19, 2022
Abstract
Alzheimer
disease
(AD)
is
the
leading
cause
of
dementia
that
affects
millions
old
people.
Despite
significant
advances
in
understanding
AD
pathobiology,
no
modifying
treatment
available.
MicroRNA‐124
(miR‐124)
most
abundant
miRNA
normal
brain
with
great
potency
to
ameliorate
AD‐like
pathology,
while
it
deficient
brain.
Herein,
authors
develop
a
DNA
nanoflowers
(DFs)‐based
delivery
system
realize
exogenous
supplementation
miR‐124
for
therapy.
The
DFs
well‐controlled
size
and
morphology
are
prepared,
chimera
attached
via
hybridization.
further
modified
RVG29
peptide
simultaneously
brain‐blood
barrier
(BBB)
penetration
neuron
targeting.
Meanwhile,
Rutin,
small
molecular
ancillary
drug,
co‐loaded
into
structure
its
intercalation
double
stranded
region.
Interestingly,
Rutin
could
synergize
suppress
expression
both
BACE1
APP,
thus
achieving
robust
inhibition
amyloid
β
generation.
nanosystem
pro‐long
circulation
vivo,
promote
BBB
targeting,
resulting
increase
hippocampus
APP/PS1
mice
therapeutic
efficacy
vivo.
Such
bio‐derived
shows
promise
as
biocompatible
nanomedicine
Frontiers in Neuroscience,
Journal Year:
2022,
Volume and Issue:
16
Published: Aug. 4, 2022
Alzheimer's
disease
(AD),
the
most
common
form
of
dementia,
is
a
progressive
and
multifactorial
neurodegenerative
disorder
whose
primary
causes
are
mostly
unknown.
Due
to
increase
in
life
expectancy
world
population,
including
developing
countries,
AD,
incidence
rises
dramatically
with
age,
at
forefront
among
diseases.
Moreover,
definitive
cure
not
yet
within
reach,
imposing
substantial
medical
public
health
burdens
every
latitude.
Therefore,
effort
devise
novel
effective
therapeutic
strategies
still
paramount
importance.
Genetic,
functional,
structural
biochemical
studies
all
indicate
that
new
efficacious
drug
delivery
interfere
different
levels
various
cellular
molecular
targets.
Over
last
few
decades,
development
nanomedicine
preclinical
stage
has
shown
progress
fast
pace,
thus
paving
way
for
its
potential
impact
on
human
improving
prevention,
diagnosis,
treatment
age-related
disorders,
AD.
Clinical
translation
nano-based
therapeutics,
despite
current
limitations,
may
present
important
advantages
innovation
be
exploited
neuroscience
field
as
well.
In
this
state-of-the-art
review
article,
we
promising
applications
polymeric
nanoparticle-mediated
bypassing
blood-brain
barrier
AD
models
boost
pharmacological
safety
efficacy.
particular,
strategic
chemical
functionalization
nanocarriers
could
successfully
employed
treating
thoroughly
described.
Emphasis
also
placed
nanotheranostics
both
diagnostic
tool
targeted
treatments.
Our
highlights
emerging
role
management
providing
readers
an
overview
nanostrategies
currently
available
develop
future
against
chronic
disease.
International Journal of Biological Sciences,
Journal Year:
2023,
Volume and Issue:
19(3), P. 721 - 743
Published: Jan. 1, 2023
Extracellular
vesicles
are
secreted
by
a
wide
variety
of
cells,
and
their
primary
functions
include
intercellular
communication,
immune
responses,
human
reproduction,
synaptic
plasticity.Their
molecular
cargo
reflects
the
physiological
processes
that
cells
origin
undergoing.Thus,
many
studies
have
suggested
extracellular
could
be
promising
biomarker
tool
for
diseases,
mainly
due
to
biological
relevance
easy
accessibility
broad
range
body
fluids.Moreover,
since
composition
leads
them
cross
blood-brain
barrier
bidirectionally,
growing
evidence
points
as
emerging
mirrors
brain
diseases
processes.In
this
regard,
review
explores
biogenesis
vesicles,
role
in
different
pathological
processes,
potential
clinical
practice,
recent
outstanding
about
exosomes
major
such
Alzheimer's
disease
(AD),
Parkinson's
(PD),
multiple
sclerosis
(MS),
amyotrophic
lateral
(ALS),
or
tumors.
Journal of Nanobiotechnology,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: Dec. 13, 2023
Neurons
and
their
connecting
axons
gradually
degenerate
in
neurodegenerative
diseases
(NDs),
leading
to
dysfunctionality
of
the
neuronal
cells
eventually
death.
Drug
delivery
for
treatment
effected
nervous
system
is
notoriously
complicated
because
presence
natural
barriers,
i.e.,
blood-brain
barrier
blood
cerebrospinal
fluid
barrier.
Palliative
care
currently
standard
many
diseases.
Therefore,
programs
that
target
disease's
origin
rather
than
its
symptoms
are
recommended.
Nanotechnology-based
drug
platforms
offer
an
innovative
way
circumvent
these
obstacles
deliver
medications
directly
central
system,
thereby
enabling
several
common
neurological
problems,
Alzheimer's,
Parkinson's,
Huntington's,
amyotrophic
lateral
sclerosis.
Interestingly,
combination
nanomedicine
gene
therapy
enables
targeting
selective
mutant
genes
responsible
progression
NDs,
which
may
provide
a
much-needed
boost
struggle
against
Herein,
we
discussed
various
obstacles,
followed
by
detailed
insight
into
recently
developed
techniques
restore
function
via
differentiation
neural
stem
cells.
Moreover,
comprehensive
background
on
role
controlling
neurogenesis
explained.
Additionally,
numerous
phytoconstituents
with
neuroprotective
properties
molecular
targets
identification
management
NDs
also
deliberated.
Furthermore,
ongoing
clinical
trials
marketed
products
provided
this
manuscript.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(1), P. 298 - 298
Published: Jan. 16, 2023
Neurodegenerative
diseases
constitute
a
group
of
pathologies
whose
etiology
remains
unknown
in
many
cases,
and
there
are
no
treatments
that
stop
the
progression
such
diseases.
Moreover,
existence
blood–brain
barrier
is
an
impediment
to
penetration
exogenous
molecules,
including
those
found
drugs.
Exosomes
extracellular
vesicles
secreted
by
wide
variety
cells,
their
primary
functions
include
intercellular
communication,
immune
responses,
human
reproduction,
synaptic
plasticity.
Due
natural
origin
molecular
similarities
with
most
cell
types,
exosomes
have
emerged
as
promising
therapeutic
tools
for
numerous
Specifically,
neurodegenerative
shown
be
potential
target
this
nanomedicine
strategy
due
difficult
access
brain
strategy’s
pathophysiological
complexity.
In
regard,
review
explores
important
biological-origin
drug
delivery
systems,
innovative
isolation
methods
exosomes,
physicochemical
characterization,
loading,
cutting-edge
functionalization
strategies
them
within
brain,
latest
research
studies
diseases,
future
challenges
nanomedicine-based
tools.